- Home
- PETZ vs HOTH Comparison
PETZ vs HOTH Comparison
Compare PETZ & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- HOTH
- Stock Information
- Founded
- PETZ 2002
- HOTH 2017
- Country
- PETZ China
- HOTH United States
- Employees
- PETZ N/A
- HOTH N/A
- Industry
- PETZ Steel/Iron Ore
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- HOTH Health Care
- Exchange
- PETZ Nasdaq
- HOTH Nasdaq
- Market Cap
- PETZ 9.3M
- HOTH 8.3M
- IPO Year
- PETZ 2017
- HOTH 2019
- Fundamental
- Price
- PETZ $0.98
- HOTH $1.14
- Analyst Decision
- PETZ
- HOTH Strong Buy
- Analyst Count
- PETZ 0
- HOTH 3
- Target Price
- PETZ N/A
- HOTH $4.00
- AVG Volume (30 Days)
- PETZ 11.1K
- HOTH 3.0M
- Earning Date
- PETZ 04-28-2025
- HOTH 05-12-2025
- Dividend Yield
- PETZ N/A
- HOTH N/A
- EPS Growth
- PETZ N/A
- HOTH N/A
- EPS
- PETZ 0.26
- HOTH N/A
- Revenue
- PETZ $563,726.00
- HOTH N/A
- Revenue This Year
- PETZ N/A
- HOTH N/A
- Revenue Next Year
- PETZ N/A
- HOTH N/A
- P/E Ratio
- PETZ $4.77
- HOTH N/A
- Revenue Growth
- PETZ 74664.72
- HOTH N/A
- 52 Week Low
- PETZ $0.65
- HOTH $0.58
- 52 Week High
- PETZ $1.74
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- PETZ 44.43
- HOTH 51.11
- Support Level
- PETZ $0.90
- HOTH $1.15
- Resistance Level
- PETZ $1.05
- HOTH $1.34
- Average True Range (ATR)
- PETZ 0.07
- HOTH 0.13
- MACD
- PETZ -0.01
- HOTH -0.02
- Stochastic Oscillator
- PETZ 31.62
- HOTH 19.44
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.